RhoVac AB is expanding its international presence by attending conferences and by increasing activity on digital media

5 December, 2017

In alignment with company’s strategy to license or sell, whole or part of operations, following completion of the ongoing phase I/II clinical trial, RhoVac AB (“RhoVac”) is attending business meetings at international conferences and is strengthening its online presence on digital media.

Getting closer to reporting of RhoVac’s phase I/II clinical trial in Q2 2018, and in accordance with our strategy to find partners for further development of the company’s RV001 cancer vaccine, RhoVac has increased its international business development activities.

Company’s management presented RhoVac at London conference Inv€$tival Showcase on November 14th, where they had meetings with international pharmaceutical- and biotechnology companies, and investors. RhoVac was also present at London Jefferies Global Healthcare Conference, known as the largest healthcare-dedicated conference in Europe with 3,400 investor and business meetings.

To further grow its communications with potential partners and investors, RhoVac has built a short video animation explaining the concept behind company’s therapeutic cancer vaccine. In the video, Anders Ljungqvist, RhoVac’s CEO, explains how the RV001 cancer vaccine, by empowering the bodies’ immune system, can suppress cancer metastasis.

The video has been published on multiple channels:
YouTube: https://www.youtube.com/watch?v=Ds5pAZ39Uys
LinkedIn: https://www.linkedin.com/company/1568600/
RhoVac website: https://www.chosaoncology.com

RhoVac’s Presentation in Inv€$tival Showcase on November 14th is also now available online and can be found on company’s website and on YouTube: https://www.youtube.com/watch?v=6FuPr9eXxjA

For more information, please contact:
Anders Ljungqvist – VD, RhoVac AB
Telefon: +45 4083 2365
E-post: alj@rhovac.com

About RhoVac AB
RhoVac AB conducts research and development of immunotherapeutic drugs. The company’s main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac’s first drug candidate has completed pre-clinical phase and clinical phase I / II study has started spring 2017. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on Spotlight Stock Market, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com